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Background: Hypogonadotropic hypogonadism (HH) in men results in insufficient testicular function and deficiencies
in testosterone and spermatogenesis. Combinations of human chorionic gonadotropin (hCG) and recombinant
follicle-stimulating hormone (recFSH) have been successful in the treatment of HH. Corifollitropin alfa is a long-acting
FSH-analog with demonstrated action in women seeking infertility care. The aim of this study was to investigate the
efficacy and safety of corifollitropin alfa combined with hCG to increase testicular volume and induce spermatogenesis
in men with HH.
Methods: This was a Phase III, multi-center, open-label, single-arm trial of corifollitropin alfa in azoospermic men aged
18 to 50 years with HH. After 16 weeks of pretreatment of 23 subjects with hCG alone, 18 subjects with normalized
testosterone (T) levels who remained azoospermic entered the 52-week combined treatment phase with hCG
twice-weekly and 150 μg corifollitropin alfa every other week. The increase in testicular volume (primary efficacy endpoint)
and induction of spermatogenesis resulting in a sperm count ≥1 × 106/mL (key secondary efficacy endpoint) during
52 weeks of combined treatment were assessed. Safety was evaluated by the presence of anti-corifollitropin alfa antibodies
and the occurrence of adverse events (AEs).
Results: Mean (±SD) testicular volume increased from 8.6 (±6.09) mL to 17.8 (±8.93) mL (geometric mean fold
increase, 2.30 [95% CI: 2.03, 2.62]); 14 (77.8%) subjects reached a sperm count ≥1 × 106/mL. No subject developed
confirmed anti-corifollitropin alfa antibodies during the trial. Treatment was generally well tolerated.
Conclusions: Corifollitropin alfa 150 μg administrated every other week combined with twice-weekly hCG for
52 weeks increased testicular volume significantly, and induced spermatogenesis in >75% of men with HH who had
remained azoospermic after hCG treatment alone.
Trial registration: ClinicalTrials.gov: NCT01709331.
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Male hypogonadotropic hypogonadism (HH) is charac-
terized by impairment in the secretion of the pituitary
gonadotropins, follicle-stimulating hormone (FSH), and
luteinizing hormone (LH), resulting in insufficient
testicular function and deficiencies in testosterone (T)
and spermatogenesis [1, 2]. The onset of HH prior to
adolescence results in delayed or absent puberty with
the respective clinical consequences, whereas onset in
adult life leads to hypogonadism with loss of androgenicity
and infertility [1, 2]. The approach to treatment of HH in
males varies based on the desired outcome; T or human
chorionic gonadotropin (hCG) therapy alone are suffi-
cient to induce virilization. However, treatment with
gonadotropins (LH and FSH) or gonadotropin-releasing
hormone (GnRH) is required to improve testicular func-
tion and induce spermatogenesis [1, 2]. The hormone
hCG has been successfully used to replace LH-activity
since the 1950s. For FSH-activity, human menopausal
gonadotropin (hMG) became available in the 1960s [3, 4]
before recombinant FSH was synthesized in the 1990s and
became the standard therapy for replacement in HH
patients for stimulation of spermatogenesis [5]. In a previ-
ous clinical trial of recombinant FSH (recFSH; Puregon®)
in men with HH (N = 30), hCG in combination with
recFSH resulted in a doubling of the combined testicular
volume from 11.4 to 24.0 mL, and achievement of sperm
counts ≥1 × 106 in 14 of 30 (47%) men who had remained
azoospermic after T levels had been normalized during
16 weeks of pretreatment with hCG alone [6]. However,
due to the short half-life of FSH, recFSH needs to be
injected 3 times per week for extended periods of several
months to years.
Corifollitropin alfa (MK-8962; formerly Org 36286/
SCH 900962) is a recombinant gonadotropin consisting
of the α-subunit of human FSH and a hybrid subunit
composed of the sequence of the β-subunit of human
FSH and the carboxy-terminal peptide part of the
β-subunit of hCG. In women seeking infertility care,
treatment with corifollitropin alfa produced a similar
therapeutic response compared with that of recFSH
[7–9]. Corifollitropin alfa has the same pharmacody-
namic (PD) profile as recFSH, but an approximately
two-fold longer elimination half-life (t1/2) and an
almost four-fold extended time interval to peak serum
levels relative to that of recFSH [10]. As a result, a
single injection of corifollitropin alfa replaces 7 days
of daily recFSH. Since treatment of HH in males usually
requires long-term treatment with frequent injections of
recFSH, the use of corifollitropin alfa, requiring fewer
injections, may result in fewer medication errors and
improved compliance.
The majority of clinical trials comparing corifollitropin
alfa with daily recFSH have been conducted in womenundergoing controlled ovarian stimulation for the
development of multiple follicles and pregnancy for
assisted reproductive technology (ART). A Phase 1,
open-label trial with corifollitropin alfa conducted in
13 men with HH demonstrated that a single dose of
15 μg corifollitropin alfa was able to induce an increase in
serum inhibin-B concentrations [11]. The objective of the
present study was to investigate the efficacy and safety of
corifollitropin alfa in combination with hCG to increase
testicular growth and induce spermatogenesis resulting in
a sperm count ≥1 × 106/mL in adult men with HH who
remained azoospermic after treatment with hCG alone.
Methods
Study design and population
This was a phase III, multi-center, open label, single-arm
trial conducted in 13 centers in Australia, Germany,
Italy, Poland, Spain, and the United Kingdom from
February 14, 2013 to April 8, 2015 (Protocol: MK-8962-
031-01, formerly known as SCH 900962, P07937;
ClinicalTrials.gov: NCT01709331). The study protocol
was approved by the institutional review boards at every
study center and informed consent was obtained before
the initiation of any study procedures. The study was
conducted in accordance with the principles of Good
Clinical Practice and applicable country and/or local
statutes and regulations regarding ethical committee
review, informed consent, and the protection of human
subjects participating in biomedical research.
The study design is illustrated in Additional file 1:
Figure S1. The trial began at Week -16 with an hCG-
only pretreatment phase, during which eligible men with
HH were treated with 1500 IU of hCG (Merck & Co.,
Inc., Kenilworth, NJ, USA) administered subcutaneously
(SC) twice-weekly for 16 weeks to normalize T levels
and to determine if hCG alone would be sufficient to
achieve spermatogenesis. The dose could be increased to
3000 IU twice-weekly after 8 weeks if the Total T level
remained below the unequivocal lower limits of the nor-
mal range (8.68 nmol/L [250 ng/dL]). Continuation into
the 52-week combined treatment phase (corifollitropin
alfa with hCG) was limited to subjects with normalized
T levels who remained azoospermic at the conclusion of
the pretreatment phase.
Day 1 of the trial was the first day of the 52-week
combined treatment phase (corifollitropin alfa with
hCG). During this phase, subjects received corifollitropin
alfa (150 μg SC) once every two weeks in addition to
twice-weekly hCG. The initial hCG dose in the com-
bined treatment phase was the same as the final dose in
the pretreatment phase; the dose was then adjusted up
to 3000 IU or down to 1500 IU as needed to maintain
Total T and estradiol (E2) levels within acceptable ranges
according to the investigator’s discretion. hCG was
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Thursday or Tuesday/Friday), and corifollitropin alfa was
given on one of the days when hCG was administered.
The final follow-up visit occurred at least 21 days
after the last dose of corifollitropin alfa and at least
seven days after the last dose of hCG. At this visit,
all subjects were assessed for any adverse events
(AEs) that occurred after the administration of the
last dose of trial medication. Blood samples were
collected for the last assessment of hormones and
anti-drug antibodies. Information was also collected
on any treatment the subjects received, for either AEs
or for the treatment of HH, after the trial.
Men between 18 and 50 years, with congenital or
acquired HH, who had azoospermia, low circulating
levels of gonadotropins (FSH and LH ≤2 IU/L) and T
(≤6 nmol/L), presence of scrotal testes, adequate
replacement of other pituitary hormones (if applicable),
good general physical and mental health, and ability and
willingness to comply with the protocol and provide
written informed consent were included in the study.
Important exclusion criteria included the presence of
primary hypogonadism (e.g., Klinefelter syndrome),
history of unilateral or bilateral cryptorchidism, and
history or presence of testicular pathology of clinical im-
portance and/or vasectomy. Men who were treated with
FSH, hCG, or GnRH within the previous 3 months or
for >1 month within the previous 6 months before sign-
ing informed consent were excluded. Other exclusion
criteria were hypophysectomy within 6 months prior to
screening, past or present oncologic treatment, diabetes
mellitus, untreated hyperprolactinemia, uncontrolled
non-gonadal endocrinopathies (thyroid, adrenal, pituitary
disorders), history of alcohol or drug abuse, and adminis-
tration of hormonal preparations, agents known to impair
testicular function or affect sex hormone secretion, and
known or suspected teratogens within 1 month before the
start of screening. Prior use of androgen preparations was
permitted if the patient underwent the wash-out period to
bring the total T down to ≤6 nmol/L (173 ng/dL).
Endpoints
The primary efficacy endpoint was the change from Day
1 to Week 52 (i.e., during the combined treatment
phase) in log-transformed testicular volume (measured
as the sum of ultrasound determination of volumes of
left and right testes). The key secondary efficacy end-
point was the percentage of subjects with induced
spermatogenesis resulting in a sperm count ≥1 × 106/mL
at any time point at or before Week 52. Other secondary
efficacy endpoints included serum concentrations of the
hormones T, E2, FSH, sex hormone-binding globulin
(SHBG), inhibin B, anti-Müllerian hormone (AMH), and
luteinizing hormone (LH) measured during the combinedtreatment phase. The primary safety endpoint was the
development of anti-corifollitropin alfa antibodies.
Efficacy assessments
Determination of testicular volume and semen analysis
Testicular ultrasound was performed to measure and
record the maximum longitudinal, antero-posterior, and
transverse diameters, and evaluate the sonographic
pattern of each testis at weeks -16, -8, and -1 of the
hCG pretreatment phase, the first day of administration
of corifollitropin alfa, every 4 weeks between weeks 4 to
52, and at discontinuation if the subject in the combined
treatment phase withdrew before week 52.
Semen samples (produced by masturbation after
sexual abstinence for at least 48 h) at screening, week -1
(last week of the hCG pretreatment phase and prior to
start of the combined treatment phase), weeks 16, 28,
40, and 52, and discontinuation in subjects who with-
drew prior to week 52, were analyzed according to the
WHO manual (2010) [12]. Investigational sites received
training for the standard operating procedures of semen
analysis prior to the start of study. Analyses for semen
volume, sperm density, motility, and morphology were
performed at local semen laboratories using standard-
ized methodology across all study sites. Azoospermia
was diagnosed if no spermatozoa were found in the sedi-
ment of a centrifuged sample.
Endocrine parameters
Blood samples were collected before the injection(s) of
hCG or corifollitropin alfa for the measurement of T, E2,
FSH, SHBG, inhibin B, AMH, and LH at weeks -16, -8,
and -1 of the hCG pretreatment phase, the first day of
administration of corifollitropin alfa, every 4 weeks
between weeks 4 to 52, at discontinuation if the subject
in the combined treatment phase withdrew before week
52, and at the follow-up visit. Total T and E2 concentra-
tions were determined centrally by Quest, Valencia, CA,
USA, using liquid chromatography–mass spectrometry
(LCMS). Serum FSH, SHBG, and LH concentrations
were determined centrally by Analytical Biochemical
Laboratory (ABL), Assen, The Netherlands, using kits
for time-resolved fluoroimmunoassays (AutoDelfia,
Wallac Oy, Finland). Inhibin B and AMH serum concen-
trations were analyzed centrally by ABL, Assen, The
Netherlands, using a validated enzyme immunoassay
(EIA) kit (Gen II ELISA; Beckman Coulter, Chaska,
MN, USA).
Safety assessments
Adverse events (AEs) and serious AEs (SAEs) were
assessed throughout the study. Routine blood chemistry,
hematology, urinalysis, physical and andrological exami-
nations, and body weight, height, blood pressure, and
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the study. Development of anti-corifollitropin alfa anti-
bodies was a primary safety endpoint. Serum samples
were collected for the assessment of anti-corifollitropin
alfa antibodies at weeks -16 and -1 of the hCG pretreat-
ment phase, weeks 4, 16, 28, 40, and 52, at discontinu-
ation if the subject in the combined treatment phase
withdrew prior to week 52, and at the follow-up visit.
All blood sampling for antibodies was performed prior
to the scheduled injection(s) of hCG or corifollitropin
alfa for that day. Other events of clinical interest
included elevated aspartate aminotransferase (AST) or
alanine aminotransferase (ALT) ≥3 × the upper limit of
normal (ULN) and elevated total bilirubin ≥2 × ULN and
simultaneous alkaline phosphatase <2 × ULN and hyper-
sensitivity reactions (skin rash, urticaria, hypotension,
allergic asthma, chest tightness, bronchospasm, dyspnea,
or wheezing following injection with corifollitropin alfa).
Statistical analyses
It was initially planned that 40 to 50 subjects would
be screened. Assuming a screen failure rate of 50 to
60%, this would result in about 20 subjects that were
expected to enter the hCG pretreatment phase. A
minimum of 10 subjects with normalized T levels who
remained azoospermic at the end of the pretreatment phase
were expected to enter the combined treatment phase.
Sample size estimates were based on the results from a pre-
vious trial with recFSH in HH men [6]. The geometric
mean increase in testicular volume during 48 weeks of
recFSH treatment was 1.77 or, equivalently, 0.57 on
log-scale (base e = 2.178) with a standard deviation (SD) of
0.36 (n = 16). Under the assumptions of a delta of 0.55 and
a SD of 0.4 (both on the log-scale) and a one-sided signifi-
cance level alpha of 0.025, a total of 10 azoospermic men
(with normalized T levels after 16 weeks of hCG pretreat-
ment) are sufficient for a 90% power to statistically demon-
strate an increase of testicular volume following the
addition of corifollitropin alfa to hCG treatment. In
addition, when either the increase from Day 1 is somewhat
smaller (e.g., 0.45 on log-scale) or the variation is somewhat
larger (e.g., 0.5 on log-scale), the power is close to 90%.
Efficacy analyses were based on the Full Analysis Set
population, including all subjects who received any dose
of corifollitropin alfa and who had a baseline and at least
one post-baseline measurement of the efficacy variable
in question. The mean change from Day 1 (first day of
the combined treatment phase) in log-transformed
testicular volume was analyzed using a mixed model
with a fixed-effect for time point and a random effect
for subject. The mixed model accounted for missing
data, assuming that data were missing at random. In
addition, Last Observation Carried Forward approaches
were performed for sensitivity analyses. For each timepoint (i.e., Weeks 4 to 52), the mean change from Day 1
to that time point and the associated 95% CI were calcu-
lated. The geometric mean increase in testicular volume
and its 95% CI were obtained by exponentiation. For
secondary efficacy endpoints, summary statistics in-
cluded the number of observations, mean, SD, median,
minimum, and maximum for continuous variables;
frequency distributions were provided for categorical
variables. For endocrine parameters, values below the
lower limit of quantitation (LLOQ) were set to 0.5 × LLOQ
for the calculation of descriptive statistics. For each
parameter, descriptive statistics were calculated per
assessment, including the ‘last measurement’ assessment
and the minimum and maximum post-baseline value. The
calculations were also performed for the absolute and
percentage changes from baseline.
Safety analyses were based on all subjects treated, in-
cluding all subjects who received any dose of corifollitropin
alfa. Summary statistics and/or incidence rates were
provided for descriptive safety endpoints including AEs,
deaths, laboratory parameters, vital signs, and body weight.
Results
Disposition of subjects
The flow of participants through the study is illustrated in
Additional file 2: Figure S2. All subjects were white males
who ranged in age from 20 to 50 years (mean: 31.5 years).
The mean weight of subjects was 84.0 kg and the mean
BMI was 26.4 kg/m2. In the 14/18 men with a hypothal-
amic cause of hypogonadism, 11 presented with Kallmann
syndrome, 2 were diagnosed with idiopathic HH, and 1
had other causes for HH. In the 4/18 men with a pituitary
cause of hypogonadism, 3 subjects were diagnosed with
panhypopituitarism (1 with coincident pituitary tumor)
and 1 had pituitary malformation. In the overall popula-
tion, 1 subject had received previous treatment with
GnRH and 7 subjects with gonadotropins.
Testicular size
Over the 52-week combined treatment phase, the
mean testicular volume (±SD) increased from 8.6
(±6.09) to 17.8 (±8.93), with a geometric mean fold
increase of 2.30 (95% CI: 2.03, 2.62). Starting from
Week 4, the mean testicular volume increased and
stabilized after Week 16 of the 52-week combined
treatment phase (Fig. 1). The results for the left and
right testes were consistent with that of total testicu-
lar volume (data not shown). During this period, 7/18
(39%) subjects had the twice-weekly dose of hCG
uptitrated from 1500 IU to 3000 IU.
Induction of spermatogenesis
Fourteen (77.8%) subjects achieved a sperm count of
≥1 × 106/mL at one of their assessments from the Day 1
Fig. 1 Mean (±SD) testicular volume at each study visit from
pretreatment baseline to Week 52 of the combined treatment phase
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combined treatment phase up to Week 52 (i.e., the end
of the combined treatment phase). The mean sperm
concentration increased from 0 at Day 1 to 5.2 × 106/mL
at Week 52 (Fig. 2a). The total sperm count over the
course of the combined treatment phase is illustrated in
Fig. 2b. By the end of the combined treatment phase, anFig. 2 a Mean (±SD) sperm concentration (×106) from Day 1 to
Week 52 of the combined treatment phase; b Total sperm count
(×106/ejaculate) during the combined treatment phaseoverall mean fraction (±SD) of 26.4% (±15.6%) of pro-
gressively motile sperm cells were observed, and the
overall mean percentage of morphologically normal
sperm cells was 11.4% (±18.5%) (Fig. 3).
Hormonal responses
Figure 4 illustrates the serum hormone levels from baseline
to Week 52 of the combined treatment phase. During the
16-week hCG-only pretreatment phase, mean serum T
levels increased from 65.2 ng/dL to 437.6 ng/dL; men who
continued into the combined treatment phase had an
additional mean increase of 297.8 ng/dL (from 409.7 ng/dL
at Day 1 to 669.8 ng/dL at Week 52). E2 levels rose from
6.8 to 25.6 pg/mL in the pretreatment phase, with an
additional mean increase of 13.4 pg/mL by Week 52 in the
combined treatment phase. FSH levels did not change
during the pretreatment phase of the trial, and increased
from a median of 0.5 mIU/mL on Day 1 to 6.6 mIU/mL by
Week 52 in the combined treatment phase. Most of this in-
crease occurred during the first 8 weeks, after which time
FSH levels remained stable to the end of the study and then
decreased to near Day 1 levels (0.5 mIU/mL) by the final
follow-up visit when treatment had been discontinued
(≥21 days after the last dose of corifollitropin alfa andFig. 3 a Mean (±SD) percentage of progressively motile sperm
during the combined treatment phase; b Mean (±SD) percentage of
normal morphology sperm during the combined treatment phase
Fig. 4 a–f Mean (±SD) hormone levels from pretreatment baseline to Week 52 of the combined treatment phase
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levels remained fairly constant over the treatment period.
Inhibin-B levels remained relatively stable during the hCG-
only pretreatment phase, but showed a mean increase
during the combined treatment phase, from 51.3 pg/mL
(±46.92) on Day 1 to 98.6 pg/mL (±44.28) at Week 52 (1.9
fold increase). Mean AMH levels declined slightly during
the pretreatment phase of the trial, from 24.0 to 13.7 ng/mL,
and a greater drop (>2-fold) occurred during the com-
bined treatment phase. The levels of LH did not change
during either the pretreatment phase or the combined
treatment phase (data not shown).
Safety
No subject developed confirmed anti-corifollitropin alfa
antibodies during this trial. A total of 11 (61.1%) subjects
had one or more AEs during the combined treatment
phase (Additional file 3: Table S1). The most frequently
reported AEs were nasopharyngitis (22.2%), estradiol in-
creased (16.7%), and headache (16.7%); the remaining
AEs were reported in two or fewer subjects. Five (27.8%)subjects had AEs that were considered by the investiga-
tors to be drug-related. The most frequently reported
drug-related AEs were estradiol increased (n = 3), blood
testosterone increased (n = 2), and blood testosterone
decreased (n = 2); there were no other AEs considered to
be drug-related reported in more than one subject
during the combined treatment phase. There were no
SAEs and no deaths reported during the combined treat-
ment phase. One subject was discontinued from the trial
during the combined treatment phase because of an AE
(blood testosterone increased to 1528 ng/dL at Week
32), which was considered by the investigator to be
drug-related. No clinically relevant changes in laboratory
values or vital signs were observed.
Discussion
Combined treatment with corifollitropin alfa and hCG
for 52 weeks resulted in a greater than two-fold increase
in testicular volume in men with HH who remained
azoospermic after 16 weeks of treatment with hCG
treatment alone, meeting the primary hypothesis of the
Nieschlag et al. Reproductive Biology and Endocrinology  (2017) 15:17 Page 7 of 9study. Treatment with corifollitropin alfa resulted in an in-
crease in the sperm count of ≥1 × 106/mL at or before
week 52 of the combined treatment phase in 14 of 18
(77.8%) men, meeting the key secondary hypothesis of the
study. No subject developed antibodies to corifollitropin
alfa. Treatment was generally well tolerated and no
new safety signals were identified during the conduct
of this study.
HH is a rare disease affecting both men and women.
In men, the lack of endogenous FSH and LH results in
insufficient testicular hormone production and lack of
spermatogenesis. The current treatment of pre- or post-
pubertal HH to achieve virilization and fertility requires
three-times-weekly injections of gonadotropins (2× hCG
and 3× recFSH). Whereas combined treatment with
hCG and recFSH has been successful for the treatment
of HH [6, 13–16], the use of corifollitropin alfa in place
of recFSH would reduce the number of required injec-
tions and may improve patient satisfaction and compli-
ance. This is important, as treatment for infertility is
often prolonged and may require up to two years of
continuous treatment [17].
Corifollitropin alfa resulted in an increase in Total T,
E2, and inhibin-B levels, and a corresponding decrease
in AMH levels. These changes are consistent with what
is expected prior to the onset of spermatogenesis. The
increase in T was slightly less than that observed in the
recFSH trial, but this did not appear to negatively impact
the primary or key secondary outcomes of the trial. The
FSH levels, endogenous only at baseline, endogenous
plus corifollitropin alfa levels at Week 52, increased dur-
ing the first 8 weeks of the combined treatment phase,
remained relatively stable until Week 52, and returned
to near Day 1 levels following treatment discontinuation.
This pattern is consistent with the expected outcomes of
this trial. All other laboratory values, except for AMH
which was not measured in the recFSH trial, were simi-
lar to those observed previously with recFSH [6].
Following the changes in serum hormone levels, sperm
counts increased in 14 of 18 subjects during the last half
of the trial. This finding is consistent with the time re-
quired to complete spermatogenesis. Assuming an im-
mediate response to corifollitropin alfa treatment, sperm
would not be expected to appear in seminal fluid before
approximately 75 days after initiation of treatment in an
azoospermic male. The increase in the percent of sperm
with abnormal morphology over the course of the trial
may be related to the increased number of sperm avail-
able for assessment from men who were azoospermic at
baseline, especially considering that the range of mor-
phologically abnormal sperm is 52–97% in healthy,
fertile men [12]. A similar increase (from 74.5–93.2%) in
the percentage of sperm with abnormal morphology was
observed in an earlier trial in men with HH, in whichspermatogenesis was induced with hCG and recFSH [6];
thus, the present finding is not unexpected.
The increases in testicular volume and sperm counts
observed in the present study suggest that corifollitropin
alfa can effectively replace recFSH in the treatment regi-
men of adult men with HH desiring fertility. The target
sperm count of at least 1 × 106/mL was selected based
on comparable studies showing that such concentrations
can realistically be attained within the time frame of a
clinical trial involving HH patients. For instance, in a
previous study of recFSH and hCG for the treatment of
HH, 47% of men achieved sperm counts ≥1 × 106/mL
[6]. In the current study, nearly 78% of men treated with
corifollitropin alfa and hCG reached this threshold. The
sustained elevation in serum FSH levels resulting from
corifollitropin alfa injections most likely contribute to
the high success rate of this regimen. Although sperm
concentrations and counts remained in the low range, it
should be noted that the sperm produced by these men
would be expected to have a high capacity to fertilize
eggs, either spontaneously or by intracytoplasmic sperm
injection (ICSI), as pregnancy rates of 65–90% in previ-
ous studies have been shown [4, 14, 18]. While the
chances for paternity in corifollitropin alfa-treated HH
patients should be high based on data from these previ-
ous studies, it was not one of the endpoints examined in
the present study.
Adverse events were reported for 11 (61.1%) subjects
who received corifollitropin alfa. The investigators
considered the AEs to be drug-related in 5 of these 11
subjects. The most commonly reported AEs were related
to changes in serum hormone levels (increasing or
decreasing T, or an increase in E2), and none was
reported as an SAE. One subject was discontinued from
treatment because of an increase in the Total T level to
1528 ng/dL. This level was reversible and declined after
discontinuation of treatment. The event was judged by
the investigator as likely to be drug-related. There were
no deaths reported in the trial. These findings support
the overall safety of corifollitropin alfa.
This study had several limitations. This was a single-arm
study that did not employ a control group. In addition, the
number of men included in this study was small.
Finally, sperm morphologies were performed locally, a
test that might introduce variability across laboratories;
however, all sites were trained with the standardized
methodology prior to the start of the study to mitigate the
potential for such variability.
Conclusions
In conclusion, in men with HH pretreated with hCG
alone for 16 weeks, addition of corifollitropin alfa to
ongoing hCG treatment resulted in more than a doubling
in testicular volume and an increase in sperm count to at
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increases in total T, E2, and inhibin B, and a decrease in
AMH levels. In addition, there were no new safety signals
identified, with no development of anti-corifollitropin alfa
antibodies. Taken together, these results suggest that long-
acting corifollitropin alfa can effectively and safely replace
recFSH in the treatment regimen of adult men with HH
desiring fertility. Additional studies exploring the role of
corifollitropin alfa in the treatment of male HH are
warranted.
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follicle-stimulating hormone; SAEs: Serious adverse events; SC: Subcutaneously;
SD: Standard deviation; SHBG: Sex hormone-binding globulin; T: Testosterone;
ULN: Upper limit of normal
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